The Ketamine Side Effect Tool (KSET): A comprehensive measurement-based safety tool for ketamine treatment in psychiatry

Adam Bayes*, Brooke Short, Carlos A. Zarate, Lawrence Park, James W. Murrough, Declan M. McLoughlin, Patricio Riva-Posse, Robert Schoevers, Jolien Veraart, Sagar Parikh, Paul Glue, Johnson Fam, Rupert McShane, Veronica Galvez, Donel Martin, Phern Chern Tor, Andre Brunoni, Colleen K. Loo

*Bijbehorende auteur voor dit werk

OnderzoeksoutputAcademicpeer review

10 Downloads (Pure)


Objectives: On a background of the rapidly expanding clinical use of ketamine and esketamine for treatment of depression and other conditions, we examined safety monitoring, seeking to identify knowledge gaps relevant to clinical practice.

Methods: An international group of psychiatrists discussed the issue of safety of ketamine and esketamine and came to a consensus on key safety gaps.

Results: There is no standard safety monitoring for off-label generic ketamine. For intranasal esketamine, each jurisdiction providing regulatory approval may specify monitoring. Treatment is often provided beyond the period for which safety has been demonstrated, with no agreed framework for monitoring of longer term side effects for either generic ketamine or intranasal esketamine.

Limitations: The KSET has established face and content validity, however it has not been validated against other measures of safety.

Conclusions: We recommend the Ketamine Side Effect Tool (KSET) as a comprehensive safety monitoring tool for acute and longer term side effects.

Originele taal-2English
Pagina's (van-tot)44-46
Aantal pagina's3
TijdschriftJournal of Affective Disorders
StatusPublished - 1-jul-2022

Citeer dit